As per the report published by Kings Research, the global Fecal Calprotectin Test Market was valued at USD 2,360 million in 2022. The market is projected to reach USD 3,938.9 million by 2030, growing at a CAGR of 6.78% from 2023 to 2030.
The fecal calprotectin test market is witnessing significant growth as a crucial diagnostic tool for assessing gastrointestinal health. By detecting levels of the calprotectin protein in stool samples, this non-invasive test provides valuable insights into bowel inflammation, aiding in the diagnosis and management of inflammatory bowel diseases (IBD) and related conditions. It offers a compelling alternative to invasive procedures, resulting in improved patient compliance and comfort.
The market's growth is primarily driven by the rising prevalence of IBD and the increasing demand for early and accurate diagnoses. As the incidence of IBD continues to rise globally, healthcare professionals are recognizing the importance of prompt identification and management. The fecal calprotectin test plays a vital role in differentiating IBD from other gastrointestinal conditions, enabling timely intervention and treatment.
The market's future prospects are promising, with opportunities for the development of more sensitive and user-friendly test kits. Advances in technology, such as the integration of artificial intelligence for result interpretation, have the potential to enhance the accuracy and efficiency of fecal calprotectin testing.
Moreover, the market's growth is supported by the surging adoption of non-invasive diagnostics, as healthcare providers prioritize improved patient outcomes and comfort. The fecal calprotectin test aligns with this trend, offering a convenient and reliable solution for assessing bowel inflammation.
Key Insights
- Based on test type, the enzyme-linked immunosorbent assay (ELISA) segment accounted for the highest value of USD 1,538.7 million in 2022
- Based on end-user, the diagnostic laboratories segment held the largest market share of 48.50% in 2022
- On the basis of region, North America accounted for the largest market share of 36.50% in 2022. (MEA mention below, check and make changes if need be)
Meridian, SD Biosensor and SJL Partners Join Forces to Strengthen Foothold in the Market
January 2023: Meridian Bioscience, Inc., a company offering diagnostic testing solutions and life science raw materials, along with SD Biosensor, Inc. and SJL Partners LLC, has officially concluded the acquisition of Meridian. The motive of the acquisition was to expand the industry environment on a macroeconomic level.
Rising Prevalence of Inflammatory Bowel Diseases (IBD) Propels Fecal Calprotectin Test Market Growth
The escalating incidence of inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, is a prominent driver propelling the growth of the fecal calprotectin test market. With IBD affecting millions globally, the demand for accurate and non-invasive diagnostic tools has surged.
Fecal calprotectin tests offer a valuable solution by enabling early detection and monitoring of bowel inflammation, thus assisting in effective disease management. This growing patient pool necessitates efficient and reliable diagnostics that can aid healthcare providers in making informed decisions. As healthcare systems shift toward preventive measures and personalized treatments, the increasing prevalence of IBD plays a pivotal role in driving the adoption of fecal calprotectin tests, underscoring their importance in addressing a significant global health challenge.
Middle East and Africa to experience the fastest growth of more than 9% by 2030.
Middle East and Africa is likely to be the fastest growing region and is estimated to experience a CAGR of 9.73% over 2023-2030. The prevalence of gastrointestinal diseases, including IBD, is on the rise in MEA, mainly due to changing dietary patterns, increasing urbanization, and lifestyle transitions. This has led to an increased demand for accurate diagnostic tools like the fecal calprotectin test, which aids in the early detection and management of intestinal inflammation.
Furthermore, there is increasing awareness about the importance of early disease detection and the need for personalized medicine in MEA. Governments and healthcare organizations in the region are actively promoting preventive healthcare and investing in advanced diagnostic technologies. This has created a favourable environment for the adoption of fecal calprotectin testing as a reliable and cost-effective method for monitoring intestinal inflammation. The expanding healthcare infrastructure and the establishment of strategic partnerships between global players and governments are aiding regional market growth.
Major Companies Forge Agreements to Strengthen Industry Foothold
The global fecal calprotectin test market is fragmented with key players such as Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Alpha Laboratories Ltd., EagleBio, Meridian Bioscience, Inc., Svar Life Science, BÜHLMANN, DRG International, Inc., DIAZYME LABORATORIES, INC., ALPCO, and others. Companies employ a variety of strategic measures such as acquisitions, mergers, partnerships, product introductions, and collaborations to expand their business globally and enhance their competitive position.